HDAC9 and neoplasm: In comparison with nonselective HDAC inhibitors, our newly designed HDAC1/2/6 inhibitor, SDFZ‐8, not only demonstrated more potent T cell activation and improved antigen presenting ability but also contributed to alleviating the immunosuppressive tumor environment by promoting macrophage polarization and negatively regulating PD‐1 expression (Figure 7).